

Organized by:



In collaboration with:



Under the auspices of:



MELANOMA bridge 2022

Naples, Italy
December 1st - 3rd, 2022
Royal Continental Hotel

2022

SCIENTIFIC PROGRAM

Thursday, Dec 1st, 2022 | AUDITORIUM



06:00 pm Registration**

MELANOMA BRIDGE OPENING SESSION**

Chairpersons: Paolo A. Ascierto, Francesco Marincola

07:00 pm Melanoma Awards

07:10 pm Lecture: Climbing out of the trough of disillusionment in the efficacy of radiation therapy and immunotherapy combinations**
Sandra Demaria

07:30 pm Lecture: How are we going to incorporate LAG3 blockade in melanoma?**
Michael A. Postow

07:50 pm Lecture**
Francesco Marincola

2022

SCIENTIFIC PROGRAM

Friday, Dec 2nd, 2022 | AUDITORIUM



09:30 am	Introduction and objectives Paolo A. Ascierto
	SESSION MELANOMA IS MODEL FOR CANCER RESEARCH <i>Chairpersons: Giuseppe Masucci, Magdalena Thurin</i>
09:35 am	Title to be defined Bernard A. Fox
09:50 am	Can we predict response and toxicity to ICI with a single approach? Iman Osman
10:05 am	Survivorship, Challenges in the Immune Checkpoint Inhibitor era Marc S. Ernstoff
10:20 am	Immunotherapy of uveal melanoma Soldano Ferrone
10:35 am	Discussion
10:50 am	Neoadjuvant trial design and clinical update in melanoma Alexander Menzies
11:05 am	Deciphering mechanisms of response and resistance to Treg depletion to inform new rational combinations Sergio Quezada
11:20 am	Dysbiosis in melanoma: how to score it? Laurence Zitvogel
11:35 am	Title to be defined Jeffrey E. Gershenwald
11:50 am	Loco-regional treatments for melanoma Corrado Caracò
12:05 pm	Discussion
12:20 pm	LECTURE
12:50 pm	<i>Lunch**</i>
01:50 pm	SYMPOSIUM

SCIENTIFIC PROGRAM

Friday, Dec 2nd, 2022 | AUDITORIUM



SESSION

LESS IS MORE: CRITICAL ISSUES IN CLINICAL PRACTICE

Chairpersons: Alexander M. Eggermont, Jeffrey A. Sosman

- 02:40 pm Less is more with Immunoscore
Jerome Galon
- 02:55 pm Less is more in combination therapies
Olivier Michielin
- 03:10 pm Role of adrenergic blockade in the immunotherapy efficacy
Igor Puzanov
- 03:25 pm Genomics of therapy-resistant melanoma and translational opportunities
Roger S. Lo
- 03:40 pm Trials to decrease toxicity and augment the benefit of combination checkpoint inhibition
Jeffrey S. Weber
- 03:55 pm The role of neoantigen landscape in metastatic cancer patient response to pembrolizumab
Michelle Krogsgaard
- 04:10 pm Discussion
- ## GREAT DEBATE SESSION
- Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov*
- 04:40 pm LAG3 VS IPI sequencing
Hussein A. Tawbi, Omid Hamid
- 05:10 pm Discussion
- 05:20 pm Is anti-PD1 still acceptable as comparator arm? Yes or no
Michael B. Atkins, Jeffrey A. Sosman
- 05:50 pm Discussion

SCIENTIFIC PROGRAM

Saturday, Dec 3rd, 2022 | AUDITORIUM



GREAT DEBATE SESSION

Chairpersons: **Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori**

09:30 am Adjuvant VS neoadjuvant approach for resectable stage III/IV
Axel Hauschild, Christian Blank

10:00 am Discussion

10:10 am Any role for surgery?
Alexander M. Eggermont, Jean-Jacques Grob*

10:40 am Discussion

10:50 am Stage II adjuvant: is there space for locoregional approaches? Yes or No
Jason J. Luke, Janice M. Mehnert

11:20 am Discussion

11:30 am *Coffee Break***

11:40 am **SYMPOSIUM**

12:30 pm **SYMPOSIUM**

01:20 pm *Lunch***

SESSION EMERGENT STRATEGIES

Chairpersons: **Nicola Normanno, Giuseppe Palmieri**

02:15 pm The future of non-melanoma skin cancers
Paolo A. Ascierto

02:30 pm Identification of high-risk melanoma patients with gene expression profiling assays
Claus Garbe

02:45 pm Melanoma induced metabolically deranged CD8+ T cells are associated with immunotherapy resistance
Brian R. Gastman

03:00 pm Modulating the liver immune microenvironment for the treatment of uveal melanoma
Richard D. Carvajal

03:15 pm New therapeutic targets revealed through germline genetic polymorphisms
Thomas F. Gajewski

* *Invited*

**Not included in the CME accredited program

SCIENTIFIC PROGRAM

Saturday, Dec 3rd, 2022 | AUDITORIUM



- 03:30 pm TIL Therapy in Melanoma: The Future is Now
Allison Betof-Warner
- 03:45 pm Dendritic cells and combinatorial adjuvants reprogram TME and lymphoid tissues for enhanced effectiveness of PD1 blockade
Pawel Kalinski
- 04:00 pm Next generation strategies to target MAPK signaling in cancer
Poulikos I. Poulikakos
- 04:15 pm Discussion
- 04:45 pm Putting it all together – Practical Considerations for Monday Clinic
Sanjiv S. Agarwala
- 05:00 pm Conclusions
Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

2022